Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer

References

• Moore CS, Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012;180: 12–6.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387–92.
   PubMed Web of Science ®Google Scholar
• Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, . Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994;54:4791–7.
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 2011;378: 771–84.
   PubMed Web of Science ®Google Scholar
• Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23:7721–35.
   PubMed Web of Science ®Google Scholar
• Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003;278:40364–72.
   PubMed Web of Science ®Google Scholar
• Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469–77.
   PubMed Web of Science ®Google Scholar
• Neri A, Megha T, Bettarini F, Tacchini D, Mastrogiulio MG, Marrelli D, . Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases. Hum Pathol 2012;43:1184–91.
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, . Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307–13.
   PubMed Web of Science ®Google Scholar
• Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, . Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10: 2289–98.
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Giannopoulou I, Lazaris AC, Alexandrou P, Tsirmpa I, Markaki S, . The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003;111: 1027–36.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005;41:1690–6.
   PubMed Web of Science ®Google Scholar
• Larsen MS, Bjerre K, Giobbie-Hurder A, Laenkholm AV, Henriksen KL, Ejlertsen B, . Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Oncol 2012;51:781–9.
   PubMed Web of Science ®Google Scholar
• Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, . The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30–years experience and future promise. Acta Oncol 2008;47:506–24.
   PubMed Web of Science ®Google Scholar
• Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: A comparison between whole sections and tissue microarrays. J Clin Pathol 2007;60:397–404.
   PubMed Web of Science ®Google Scholar
• Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, . Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur J Cancer 2009;45:2528–36.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes – dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22: 1736–47.
   PubMed Web of Science ®Google Scholar
• Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, . Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 2008;26:2653–8.
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, . Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007;109:1933–9.
   PubMed Web of Science ®Google Scholar
• Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, . Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008;122: 2050–6.
   PubMed Web of Science ®Google Scholar
• Bigelow RL, Williams BJ, Carroll JL, Daves LK, Cardelli JA. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat 2009; 117:31–44.
   PubMed Web of Science ®Google Scholar
• Kuvaja P, Hulkkonen S, Pasanen I, Soini Y, Lehtonen S, Talvensaari-Mattila A, . Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status. Exp Cell Res 2012;318:1094–103.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, . Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101: 736–50.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:5222–32.
   PubMed Web of Science ®Google Scholar
• Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, . Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012; 30:729–34.
   PubMed Web of Science ®Google Scholar